Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Stocks
TEVA
IL0006290147
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,533.00 ILa | -0.88% |
|
+0.03% | -5.52% |
| 07-09 | Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus | MT |
| 07-09 | Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada | MT |
| Market Cap | 36.31B 11,152B 31.91B 29.65B 27.27B 51.12B 3,506B 52.11B 354B 138B 1,712B 136B 133B 5,949B | P/E 2026 * |
38.5x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 47.47B 14,581B 41.72B 38.76B 35.65B 66.83B 4,584B 68.13B 462B 181B 2,238B 178B 174B 7,777B | EV / Sales 2026 * |
2.85x | EV / Sales 2027 * | 2.59x |
| Free-Float |
88.61% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| 1 day | -0.88% | ||
| 1 week | +0.03% | ||
| Current month | -3.09% | ||
| 1 month | +1.64% | ||
| 3 months | -1.29% | ||
| 6 months | -3.94% | ||
| Current year | -5.52% |
| 1 week | 9,396 |  | 9,930 |
| 1 month | 9,396 | | 10,730 |
| Current year | 8,860 | | 11,350 |
| 1 year | 5,305 | | 11,350 |
| 3 years | 3,002 | | 11,350 |
| 5 years | 2,383 | | 11,350 |
| 10 years | 2,175 | | 21,200 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 01/01/2023 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 22/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 03/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 01/01/2009 |
Sol Barer
CHM | Chairman | 78 | 06/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 01/09/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.88% | +0.03% | - | - | 35.11B | |
| +1.97% | +2.53% | +52.73% | +156.66% | 1,037B | |
| +1.42% | +4.96% | +54.39% | +52.34% | 615B | |
| +1.43% | +5.25% | +37.31% | +78.74% | 448B | |
| +5.14% | +5.84% | +37.54% | +27.28% | 326B | |
| +1.85% | +4.64% | +38.53% | +39.87% | 293B | |
| -0.11% | +0.97% | +22.57% | +17.81% | 264B | |
| +0.25% | -3.10% | -24.44% | -42.25% | 216B | |
| +1.49% | +3.68% | +21.53% | +58.21% | 198B | |
| +0.40% | -0.64% | +18.78% | +62.28% | 162B | |
| Average | +0.71% | +1.12% | +28.77% | +50.10% | 395.27B | |
| Weighted average by Cap. | +0.63% | +1.47% | +38.33% | +75.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.64B 5,110B 14.62B 13.59B 12.5B 23.42B 1,606B 23.88B 162B 63.28B 784B 62.44B 61.1B 2,726B | 17.23B 5,293B 15.14B 14.07B 12.94B 24.26B 1,664B 24.73B 168B 65.54B 813B 64.68B 63.29B 2,823B |
| Net income | 1.31B 402B 1.15B 1.07B 983M 1.84B 126B 1.88B 12.75B 4.98B 61.73B 4.91B 4.81B 214B | 2.46B 757B 2.17B 2.01B 1.85B 3.47B 238B 3.54B 23.99B 9.37B 116B 9.25B 9.05B 404B |
| Net Debt | 11.16B 3,429B 9.81B 9.12B 8.38B 15.72B 1,078B 16.02B 109B 42.46B 526B 41.9B 41B 1,829B | 8.41B 2,582B 7.39B 6.86B 6.31B 11.83B 812B 12.06B 81.87B 31.97B 396B 31.55B 30.87B 1,377B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/07/26 | ILA 9,533.00 | -0.88% | 1,061,041 |
| 21/07/26 | ILA 9,618.00 | -0.25% | 1,288,336 |
| 20/07/26 | ILA 9,642.00 | -0.96% | 759,073 |
| 17/07/26 | ILA 9,735.00 | -0.41% | 485,235 |
| 16/07/26 | ILA 9,775.00 | +2.57% | 1,284,861 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TEVA Stock
- TEVA Stock
Select your edition
All financial news and data tailored to specific country editions
